Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205426 · ClinicalTrials.gov registry record · Phase 4
Natrecor for Pulmonary Hypertension in Lung Transplants
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00205426 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 7 participants.
The verdict
NCT00205426, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO use by matched historical controls.
Interventions
- DRUG Natrecor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205426
The ClinicalTrials.gov registry entry for NCT00205426 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natrecor is the first listed.
NCT00205426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205426 about?
NCT00205426 is a clinical study titled "Natrecor for Pulmonary Hypertension in Lung Transplants". This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historic...
What is the current status of trial NCT00205426?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2005-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00205426?
The interventions under investigation include: Natrecor (DRUG).
Who is sponsoring clinical trial NCT00205426?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.